NO952194L - Spirofuranone derivatives and their use in the treatment of neurodegenerative diseases - Google Patents

Spirofuranone derivatives and their use in the treatment of neurodegenerative diseases

Info

Publication number
NO952194L
NO952194L NO952194A NO952194A NO952194L NO 952194 L NO952194 L NO 952194L NO 952194 A NO952194 A NO 952194A NO 952194 A NO952194 A NO 952194A NO 952194 L NO952194 L NO 952194L
Authority
NO
Norway
Prior art keywords
alkyl
treatment
spirofuranone
derivatives
optionally substituted
Prior art date
Application number
NO952194A
Other languages
Norwegian (no)
Other versions
NO952194D0 (en
Inventor
Alexander Kover
Iii James Loch
George Mullen
Edwin Shen-Chou Wu
Original Assignee
Fisons Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929225497A external-priority patent/GB9225497D0/en
Priority claimed from GB929225498A external-priority patent/GB9225498D0/en
Priority claimed from GB939316531A external-priority patent/GB9316531D0/en
Application filed by Fisons Corp filed Critical Fisons Corp
Publication of NO952194L publication Critical patent/NO952194L/en
Publication of NO952194D0 publication Critical patent/NO952194D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forbindelser av formel (I), hvori ring A er en ring av formel (AI) eller (All) (hvori splroatonet er angitt ved "). R1 betyr H eller alkyl-C^; R^ betyr -(CH2)n-OR^. -(CH^-CfOjR4. fluoralkyl-C^. cyanoalkyl-C eller alkyl-C., substituert med en 4-7-leddet eventuelt umettet heterocykllsk ring; R3 betyr H, alkyl-C , (eventuelt substituert med alkoksy-C., ), cykloalkyl-C,_7. en 4-7-leddet eventuelt unettet heterocykllsk ring, fenyl (eventuelt substituert med halogen, hydroksy eller alkyl-C., ), eller benzyl (eventuelt substituert med halogen, hydroksy eller alkyl-C.,); R4 betyr OR5, NR^7. N(OR6)R7 eller alkyl-C. ,; R5 betyr H, alkenyl-C , alkynyl- 2-6' Cg, eller alkyl-C., (eventuelt substituert med fenyl); R6 og R7 betyr uavhengig av hverandre H eller alkyl- C._,; R° betyr H eller alkyl-C. ,; n er 2-5; m er 1-5; p er l eller 2; og farmasøytisk akseptable salter derav; er nyttige ved behandlingen av neurodegeneratlve sykdomstilstander.Compounds of formula (I), wherein ring A is a ring of formula (AI) or (All) (wherein the splroatone is represented by "). R 1 is H or alkyl-C 2; R 1 is - (CH 2) - (CH2 -CfO2R4. Fluoroalkyl-C1-6 cyanoalkyl-C or alkyl-C, substituted with a 4-7 membered optionally unsaturated heterocyclic ring; R3 is H, alkyl-C C.,), cycloalkyl-C, 7. A 4-7 membered optionally unsaturated heterocyclic ring, phenyl (optionally substituted with halogen, hydroxy or alkyl-C1), or benzyl (optionally substituted with halogen, hydroxy or alkyl) R 4 means OR 5, NR 5, N (OR 6) R 7 or alkyl-C 1, R 5 means H, alkenyl-C, alkynyl 2-6 'C 9, or alkyl-C 1, (optionally substituted with phenyl); R6 and R7 independently represent H or alkyl-C, R ° means H or alkyl-C,; n is 2-5; m is 1-5; p is 1 or 2; and pharmaceutically acceptable salts thereof, are useful in the treatment of neurodegenerative disease states.

NO952194A 1992-12-05 1995-06-02 Spirofuranone derivatives and their use in the treatment of neurodegenerative diseases NO952194D0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929225497A GB9225497D0 (en) 1992-12-05 1992-12-05 Pharmacologically active compounds
GB929225498A GB9225498D0 (en) 1992-12-05 1992-12-05 Pharmacologically active compounds
GB939316531A GB9316531D0 (en) 1993-08-10 1993-08-10 Pharmacologically active compounds
PCT/GB1993/002500 WO1994013678A1 (en) 1992-12-05 1993-12-06 Spirofuranone derivatives and their use in the treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
NO952194L true NO952194L (en) 1995-06-02
NO952194D0 NO952194D0 (en) 1995-06-02

Family

ID=27266497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952194A NO952194D0 (en) 1992-12-05 1995-06-02 Spirofuranone derivatives and their use in the treatment of neurodegenerative diseases

Country Status (10)

Country Link
EP (1) EP0672046A1 (en)
JP (1) JPH08503955A (en)
KR (1) KR950704322A (en)
AU (1) AU5655394A (en)
CA (1) CA2150947A1 (en)
FI (1) FI952733A0 (en)
IL (1) IL107881A0 (en)
MX (1) MX9307679A (en)
NO (1) NO952194D0 (en)
WO (1) WO1994013678A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129793A (en) * 1997-01-27 2003-01-12 Warner Lambert Co Process for producing (z)-azabicyclo oxime ethers
TWI243173B (en) 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
ES2295963T3 (en) 2004-01-08 2008-04-16 F. Hoffmann-La Roche Ag DIAZA-SPIROPIPERIDINE DERIVATIVES AS INHIBITORS OF GLICINE TRANSPORTER 1 AND GLICINE TRANSPORTER 2.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075317A (en) * 1989-06-21 1991-12-24 Fisons Corporation Spirofurane derivatives
JPH03153690A (en) * 1989-11-10 1991-07-01 Yamanouchi Pharmaceut Co Ltd Heterocyclic spiro derivative and production thereof
IE914238A1 (en) * 1990-12-19 1992-07-01 Fisons Corp Novel spirofurane derivatives

Also Published As

Publication number Publication date
MX9307679A (en) 1994-06-30
CA2150947A1 (en) 1994-06-23
WO1994013678A1 (en) 1994-06-23
AU5655394A (en) 1994-07-04
JPH08503955A (en) 1996-04-30
KR950704322A (en) 1995-11-17
IL107881A0 (en) 1994-04-12
FI952733A (en) 1995-06-05
NO952194D0 (en) 1995-06-02
EP0672046A1 (en) 1995-09-20
FI952733A0 (en) 1995-06-05

Similar Documents

Publication Publication Date Title
NO976085L (en) The diphenylmethylene piperidine derivatives
NZ325449A (en) Naphthyl-substituted benzimidazole derivatives as anticoagulants
DK0590919T3 (en) Therapeutic agents for Parkinson's disease
NO159795C (en) PROCEDURE FOR THE PREPARATION OF 2-PENEM COMPOUNDS.
DK0632036T3 (en) Amide derivatives with antipypercholesteremic activity, their preparation and their therapeutic uses
ES2057126T3 (en) TREATMENT METHOD OF CAQUEXIA AND SOME NEW COMPOUNDS TO USE IN THIS METHOD.
ATE205206T1 (en) BENZYLIDENTHIAZOLIDINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS LIPIDE PEROXIDE INHIBITORS
KR890011596A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for treating insomnia
DE69209128D1 (en) Use of indazole methoxyalkanoic acid in the manufacture of a medicament for the treatment of autoimmune diseases
FR2617476B1 (en) NOVEL AROMATIC POLYCYCLIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND IN COSMETICS
NO952194L (en) Spirofuranone derivatives and their use in the treatment of neurodegenerative diseases
DE69828197D1 (en) AMID DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDERS OF THE NETWORK
ATE63541T1 (en) N-PHENYLETHYLAMINOALKYL BENZAMIDES AS ANTIARHYTHMIC AGENTS.
DE69518706D1 (en) Use of diphenylethane derivatives in the manufacture of a medicament for the treatment of glaucoma
NO934227L (en) Pyrrole derivatives, processes for their preparation and therapeutic use
FI810103L (en) NYA 2,3-DIHYDRO-IMIDAZO / 1,2-B / PYRIDAZINDERIVAT FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DERAS THERAPEUTIC ANVAENDNING
HK1003573A1 (en) New antibiotics of the mureidomycin group their preparation and their therapeutic use
ATE212842T1 (en) QUINOXALINE DERIVATIVES FOR THE TREATMENT OF TINNITUS
FI912733A (en) Process for the preparation of therapeutically useful / (1-arylpyrrolidin-2-yl) methyl / piperazine derivatives
DE69429447D1 (en) USE OF 2-AMINOPURINE DERIVATIVES FOR TREATMENT AND PROPHYLAXIS OF HUMAN HERPESVIRUS 7 INFECTIONS
RU94033470A (en) Cyclohexane derivatives, pharmcomposition based thereon, and method of treatment
AU621971B2 (en) Use of isocarbacyclins for preventing or treating organ diseases
ATE81465T1 (en) USE OF 2-OXO-IMIDAZOLIDINE DERIVATIVES IN THE TREATMENT OF KIDNEY DISEASES.
NO922094L (en) HEXAPEPTIDES WITH SULPHATESTER GROUPS
GR1000522B (en) Preparation method of new analogue nucleozites